FDA Investigator Lauren N Howard

Lauren N Howard has conducted inspections on 49 sites in 6 countries as of 03 Jun 2024. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
49
Last Inspection Date:
03 Jun 2024
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America, Canada, Italy, China, Germany, Bulgaria
FDA Investigators that have inspected at least one site in common with Lauren N Howard:
Alan M Barker, Allison A Aldridge, PhD, Allison C Hunter, Amanda M Dunneback, Andrew J Barrowcliff, Angela E Glenn, Anna M Brannen, Ariel Cruz Figueroa, Bailey A Uetrecht, Beatrix D Arevalo, Beatrix D Hippe, Bei Y He, Benjamin D Shuler, Benjamin J Dastoli, Bethany L Subel, Bo Chi, PhD, Brenda C Hamilton, Brenda S Zimmer, PhD, Brian A Roelofs, Brian D Rogers, Bruce H Mccullough, Bryan J Love, Bryan M Gamble, Bryce A Hammer, Byeongtaek Oh, Camerson E Moore, Carl A Huffman, III, Cassandra L Abellard, CDR Thomas R Berry, PPh, Charisse K Green, Charles C Conn, III, Charles M Edwards, Cherrie A Zachary, Cheryl A Grandinetti, Chiaochun J Wang, Christina A Miller, Christina Capacci Daniel, PhD, Christina L Bigham, Christopher T Middendorf, Christopher T Peters, Claire M Minden, Colleen E Burke, Courtney E Hillier, Craig P Seaborn, Cynthia T Cain, D Yvette Barnett, Dale A Nyberg, David P Moorhead, David S Jackson, Debra I Love, Debra Lboyd Seale, Dell S Moller, Dennis Cantellops Paite, Dilip Devineni, PhD, Djamila Harouaka, Donna F Campbell, Dr. Carmelo Rosa, Dr. Zhou Chen (nmi), MD PhD, Dyvette Arline, Edwin Martinez, Elisa A Nickum, Elisa A Weckerling, Elizabeth L Loreaux, Elizabeth Ll Edwards, Elizabeth P Kinsella, Eric M Mueller, PharmD, Frederick M Lochner, Gam S Zamil, Genevieve E Ghand, Geoffrey K Kilili, Hamet M Toure, PharmD MPH, Heather A Mccauley, Hugh M Mcclure, II, Ian L Mcwilliams, James Norman, Javonica F Penn, Jazmine N Brown, Jazmine N Still, Jeanne J Thai, Jeffrey A Sincek, Jennifer L Gustavus, Jesse A Vazquez, Jill J Tillman, Jill R Loeliger, Jill R Raezer, John A Gonzalez, Jon P Antoniou, Jose Acruz Gonzalez, Joseph A Piechocki, Joshua P Wireman, Joshua S Hunt, Joslyn K Brunelle, PhD, Kalavati Suvarna, PhD, Karen M Kondas, Kathleen D Culver, Kelli L Wilkinson, Kenneth E Felkley, Lauren N Smith, Laurie Graham, LCDR Chad N Thompson, Lequita M Mayhew, Lianji Jin, Libia M Lugo, Lindsey M Schwierjohann, Lisa Hornback, Lisa R Hilliar, Logan T Williams, Lynnsey A Renn, Marianne Allen, Maribeth G Grattan, Maribeth G Niesen, Mark E Parmon, Mary B Sheets, Massod Rahimi, PhD, Matt D Suedkamp, Matthew B Casale, Matthew H Pitts, Michael E Clark, Michael P Sheehan, Michael Shanks, MS, Michele L Glendenning, Michele L Obert, Michele Perry Williams, Monica E Murie, Muna Algharibeh, Nebil A Oumer, Nibin Varghese, MS, Nicholas J Presto, Nicholas L Paulin, Nicholas P Diorio, Nicholas Z Lu, Nicole S Williams, Nina Ni, Noreen Muñiz, Paranthaman Senthamaraikannan, Patrick L Wisor, Phillip M Pontikos, Rafael Padilla, Rafeeq A Habeeb, Richard Ledwidge (nmi), PhD, Richard T Riggie, Robbie J Alleman, Robert J Ham, Roy C Stephens, Russell K Riley, Sandra A Hughes, Shalonda C Clifford, Shannon D Fink, Shannon F Underwood, Sidney B Priesmeyer, Stephanie M Mongeluzzi, Steven C Madzo, Steven D Kehoe, Steven P Eastham, Susan D Yuscius, Sydney S Choi, Tamara M Kays, Tara L Greene, Tara L King, Tarun D Mehta, Ted L Anderson, Tenzin Jangchup, Teresa K Kastner, Thomas J Arista, Thomas W Nojek, Tracey L Harris, Tyler M Peterson, Tyra S Wisecup, Ucheabuchi Cchudi Nwankwor, Vaishali J Patel, Valerie M Steffens, Valerie M Toomey, Veronica Fuentes, MS, Vipulchandra N Dholakia, Warren J Lopicka, Wayne D Mcgrath, Wen Ning Chan (Sally), Wendy G Tan, PhD, Xiaoshi N Wang, Ying Zhang, Yiyue Zhang (nmi), PhD, Yongmin Liu, Yuanyuan Li, Yvette Mlacour Davis, Zhang Zhao, PhD, Zhigang Sun, PhD

Lauren N Howard's Documents

Publish Date Document Type Title
January, 2022 FDA 483 CIL Isotope Separations, LLC - Form 483, 2022-01-25
August, 2019 FDA 483 Resilience US, Inc. - Form 483, 2019-08-09
February, 2019 EIR Teva Women's Health LLC - EIR, 2019-02-08
January, 2018 FDA 483 Response Infusion Partners, LLC - Form 483R, 2018-02-15
July, 2022 FDA 483 Smithfield BioScience, Inc. - Form 483, 2022-07-15
March, 2018 FDA 483 Resilience US, Inc. - Form 483, 2018-03-08
September, 2022 FDA 483 The Medicine Shoppe - Form 483, 2022-09-28
December, 2021 EIR Aldrich Chemical Company LLC - EIR, 2021-12-13
January, 2020 EIR Xellia Pharmaceuticals USA LLC - EIR, 2020-01-31
December, 2021 FDA 483 Response Aldrich Chemical Company LLC - Form 483R, 2022-01-03
January, 2019 EIR Adare Pharmaceuticals, Inc. - EIR, 2019-01-25
July, 2019 EIR Allergan Sales, LLC - EIR, 2019-07-29
December, 2019 FDA 483 Patheon Pharmaceuticals Inc. - Form 483, 2019-12-13
October, 2016 FDA 483 Smithfield BioScience, Inc. - Form 483, 2016-10-27
June, 2021 FDA 483 Response Allergan Sales, LLC - Form 483R, 2021-07-15
December, 2021 FDA 483 Aldrich Chemical Company LLC - Form 483, 2021-12-13
December, 2019 EIR Patheon Pharmaceuticals Inc. - EIR, 2019-12-13
May, 2017 EIR Adare Pharmaceuticals, Inc. - EIR, 2017-05-19
September, 2019 FDA 483 LEC Custom Products, Inc - Form 483, 2019-09-12
April, 2017 EIR West-Ward Columbus Inc. - EIR, 2017-04-14
September, 2017 EIR Ohio Lab Pharma - EIR, 2017-09-28
January, 2018 FDA 483 Infusion Partners, LLC - Form 483, 2018-01-26
December, 2023 FDA 483 Patheon Biologics LLC - Form 483, 2023-12-08
July, 2019 FDA 483 Allergan Sales, LLC - Form 483, 2019-07-29
May, 2022 FDA 483 Resilience US, Inc. - Form 483, 2022-05-25
January, 2020 EIR Patheon Pharmaceuticals Inc. - EIR, 2020-01-14
September, 2017 FDA 483 Ohio Lab Pharma - Form 483, 2017-09-28
June, 2021 EIR Allergan Sales, LLC - EIR, 2021-06-24
August, 2019 EIR Resilience US, Inc. - EIR, 2019-08-09
November, 2021 FDA 483 Response Miami University - Form 483R, 2021-11-29
March, 2018 EIR Resilience US, Inc. - EIR, 2018-03-08
February, 2018 FDA 483 Vantage Specialty Ingredients, Inc. - Form 483, 2018-02-15
February, 2017 FDA 483 Foshan Flying Medical Products Co., Ltd. - Form 483, 2017-02-23
January, 2020 FDA 483 Xellia Pharmaceuticals USA LLC - Form 483, 2020-01-31
February, 2018 EIR Vantage Specialty Ingredients, Inc. - EIR, 2018-02-15
September, 2017 EIR Resilience US, Inc. - EIR, 2017-09-07
October, 2016 EIR Xellia Pharmaceuticals USA LLC - EIR, 2016-10-13
November, 2021 FDA 483 Miami University - Form 483, 2021-11-05
January, 2023 FDA 483 AbbVie Inc. - Form 483, 2023-01-31
August, 2019 FDA 483 Response Resilience US, Inc. - Form 483R, 2019-08-29
June, 2021 FDA 483 Allergan Sales, LLC - Form 483, 2021-06-24
March, 2022 FDA 483 Response TMC Acquisitions LLC dba Tailor Made Compounding - Form 483R, 2022-04-04
July, 2019 FDA 483 Response Allergan Sales, LLC - Form 483R, 2019-08-16
December, 2017 FDA 483 CIL Isotope Separations, LLC - Form 483, 2017-12-13
August, 2021 FDA 483 New Vitalis Pharmacy LLC - Form 483, 2021-08-27
May, 2019 FDA 483 Smithfield BioScience, Inc. - Form 483, 2019-05-15
March, 2022 FDA 483 TMC Acquisitions LLC dba Tailor Made Compounding - Form 483, 2022-03-14
December, 2016 FDA 483 CIL Isotope Separations, LLC - Form 483, 2016-12-02
December, 2018 FDA 483 LGM PHARMA, LLC - Form 483, 2018-12-04
April, 2024 FDA 483 Kindeva Drug Delivery L.P. - Form 483, 2024-04-03

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more